J.P. Morgan Healthcare Conference Recap: What Dealmakers Expect in 2026

Deal activity may be picking up, but expectations for 2026 are best described as cautious and practical. In this episode of "Counsel That Cares," Holland & Knight Healthcare Transactions attorney John Saran and Bailey & Company Director of Market Development Rebecca Springer recap the 44th Annual J.P. Morgan Healthcare Conference, sharing what they heard from sponsors, bankers and operators about the year ahead. They discuss the shift from "big rebound" predictions to a steady rebuild, what buyers are prioritizing in diligence and deal structuring, and where momentum is returning, including add-ons and creative investment formats. The conversation also highlights sectors drawing attention, from employer health and pharma services to applied behavioral analysis (ABA) platforms, healthcare IT's evolving AI lens, and emerging consumer health and longevity theses. Mr. Saran also breaks down the fast-changing regulatory environment surrounding private equity and corporate practice of medicine, including state transaction reporting laws, that are increasingly shaping how healthcare deals go to market. This podcast was recorded and is for informational purposes only. By accessing this podcast, you acknowledge that Bailey & Co. makes no warranty, guarantee, or representation as to the accuracy or sufficiency of the information featured. The views, information, or opinions expressed during this podcast series are solely those of the individuals involved and do not necessarily reflect those of Bailey & Co. This podcast should not be used as a substitute for competent investment advice from a licensed professional in your state and should not be construed as an offer to make or consider any investment or course of action.